微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 61.71% | -1.53% | -2.55% | 46/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 63.32% | 2.12% | -2.25% | 42/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 64.78% | 8.44% | 4.63% | 38/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 61.91% | 2.46% | -1.2% | 48/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 62.66% | 6.28% | 1.06% | 45/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 62.01% | 3.11% | 3.8% | 46/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 59.74% | 1.46% | -1.14% | 51/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 60.42% | -3.11% | 2.48% | 52/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 58.96% | -3.95% | -1.95% | 59/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 60.13% | -2.99% | 2.14% | 57/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 58.87% | -4.49% | -5.59% | 57/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 62.36% | 3.93% | 1.59% | 54/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 61.39% | 0.19% | -0.97% | 53/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 61.99% | 1.39% | 0.56% | 54/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 61.64% | -2.05% | 2.73% | 51/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 60% | -5.85% | -2.07% | 65/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 61.27% | -3.97% | 0.21% | 52/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 61.14% | -2.14% | -2.85% | 55/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 62.93% | 4.68% | -1.25% | 43/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 63.73% | 5.28% | -0.12% | 53/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 63.8% | 7.51% | 2.12% | 47/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 62.48% | 6.45% | 3.93% | 48/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 60.12% | 5.72% | -0.69% | 47/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 60.54% | 1.31% | 2.01% | 57/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 59.34% | -1.63% | 1.11% | 51/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 58.7% | 1% | 3.22% | 54/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 56.86% | 4.12% | -4.83% | 48/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 59.75% | 6.77% | -0.96% | 53/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 60.33% | 9.27% | 3.81% | 39/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 58.11% | 7.56% | 6.41% | 43/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 54.62% | 7.03% | -2.41% | 49/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 55.96% | 12.27% | 1.36% | 55/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 55.21% | 15.68% | 2.19% | 39/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 54.03% | 17.81% | 5.88% | 39/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 51.03% | 11.38% | 2.37% | 38/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 49.85% | 1.28% | 4.44% | 51/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 47.73% | 2.95% | 4.07% | 34/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 45.86% | 2.85% | 0.09% | 41/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 45.82% | 5.36% | -6.91% | 29/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 49.22% | 10.17% | 6.17% | 44/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 46.36% | 7.04% | 3.97% | 34/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 44.59% | 5.15% | 2.54% | 39/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 43.49% | 4.12% | -2.67% | 36/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |